T cell therapy for melanoma that has spread to the brain and spine lining
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment where your own immune cells (T cells) are collected, activated, and then injected into the fluid around your brain and spinal cord to fight melanoma cells that have spread there. It's for people whose melanoma has traveled to the lining of the brain or spinal cord (leptomeningeal disease).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have melanoma that has spread to the lining of your brain or spinal cord (leptomeningeal disease), shown on scans or in spinal fluid tests.
- You need to have a certain tissue type called HLA-A2 or HLA-A24 (a blood test can check this).
- You must be able to care for yourself (ECOG score 0 or 1).
- You need to have finished any radiation, chemotherapy, or other biologic treatments within a certain number of days before starting this trial.
- You must be age 18 or older.
- If you could become pregnant or get someone pregnant, you must agree to use effective birth control during and for a while after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
This trial tests a new treatment called tumor infiltrating lymphocyte (TIL) therapy for melanoma that hasn't responded to standard immunotherapy drugs. The therapy involves taking immune cells from your tumor, growing more of them in the lab, and putting them back into your body to fight the cancer.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Hear when a new Leptomeningeal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.